Navigation Links
Results of the NEXT clinical trial Reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 Researchers have found that polymer-free amphilimus-eluting stents in de novo coronary artery lesions showed a significantly lower in-stent late loss at six months compared to paclitaxel-eluting stents with permanent polymers.

Results of the NEXT trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. NEXT is a prospective, randomized trial comparing a polymer-free amphilimus-eluting stent to a paclitaxel-eluting stent.

The risk/benefit balance of coronary drug-eluting stents is still suboptimal, and the safety of coating polymers, which hold and release the drug over time, remains uncertain. Researchers sought to demonstrate the non-inferiority of polymer-free amphilimus-eluting stents versus permanent-polymer paclitaxel-eluting stents in de novo native coronary artery lesions. The primary endpoint was six-month angiographic in-stent late loss within a non-inferiority scope. Late loss is the difference between the diameter of a stented segment post-procedure compared with the follow-up angiogram.

A total of 323 patients were enrolled, with 162 randomized to amphilimus-eluting stents and 161 to paclitaxel-eluting stents. In-stent late loss was significantly lower with amphilimus-eluting stents (0.140.36 mm vs. 0.340.40 mm, P<0.0001 for non-inferiority, P<0.0001 for superiority). Clinical endpoints (cardiac death, myocardial infarction, target lesion revascularization or stent thrombosis) up to 12 months did not differ significantly.

"These results are encouraging evidence that support the use of polymer-free stents, but further studies are warranted to prove that this potent polymer-free stent can improve the risk-benefit balance of coronary drug-eluting stents," said Didier Carri, MD, PhD, the principal investigator of the trial. Dr. Carri is Professor of Medicine, Cardiology at the University of Paul Sabatier and the Head of Hemodynamics and Angioplasty Section at Rangueil Hospital in Toulouse, France.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the PEPCAD-DES trial reported at TCT 2011
2. Results of the STACCATO Trial reported at TCT 2011
3. Results of the DEB-AMI Trial reported at TCT 2011
4. Results of the RIFLE STEACS clinical trial reported at TCT 2011
5. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
6. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
7. Combination epigenetic therapy clinical trial results
8. Results of the PARIS registry Reported at TCT 2011
9. Results of the TRIGGER-PCI trial reported at TCT 2011
10. Results of rapid gene trial reported at TCT 2011
11. Results of the BRIDGE trial reported at TCT 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... ergoFET force gauges used in physical therapy, occupational therapy and sports medicine clinics, ... resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... ... 10, 2016 , ... LaserShip, a regional parcel carrier that services the eastern ... Michigan last Friday in order to aid in the Flint water crisis. In 2014, ... facility located in Clio, only 15 miles away from Flint. , “We have deep ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City Health Center ... , For nearly 23 years, Heart City Health Center has provided the Elkhart ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is excited ... bottled water brand owners that topped the list as a result of their commitment ... The premier brand was Tibet 5100, a top notch water company that specializes in ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... YORK , Feb. 11, 2016  Today, ... foot-focused suite of products designed to support health ... are custom orthotic insoles that combine years of ... partners in the podiatric field with cutting edge ... and propel . It is supported by SOLS, ...
(Date:2/11/2016)... --> ... report provides information on development trends, competitive landscape ... statistical data and information analysis. http://www.deepresearchreports.com/142870.html ... Complete report on Autoclave industry spread across ... 296 tables and figures is now available at ...
(Date:2/10/2016)... Calif., Feb. 10, 2016   Genomic Health, Inc. (Nasdaq: ... the quarter and year ended December 31, 2015. ... fourth quarter of 2015, compared with $69.1 million in the fourth ... currency basis, revenue increased 9 percent compared with the same period ... U.S. revenue was $63.9 million in the fourth quarter of ...
Breaking Medicine Technology: